Composite score of PD-1 + CD8 + tumor-infiltrating lymphocytes and CD57 + CD8 + tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer.

IF 7 2区 医学 Q1 ONCOLOGY
Tianhui He, Jie Zhang, Lin Zeng, Zhongnan Yin, Bo Yu, Xi Zhang, Xiaoxue Yang, Chunliang Shang, Lixiang Xue, Hongyan Guo
{"title":"Composite score of PD-1 <sup><b>+</b></sup> CD8 <sup><b>+</b></sup> tumor-infiltrating lymphocytes and CD57 <sup><b>+</b></sup> CD8 <sup><b>+</b></sup> tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer.","authors":"Tianhui He, Jie Zhang, Lin Zeng, Zhongnan Yin, Bo Yu, Xi Zhang, Xiaoxue Yang, Chunliang Shang, Lixiang Xue, Hongyan Guo","doi":"10.21147/j.issn.1000-9604.2025.01.06","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The expression of programmed death 1 (PD-1) on CD8<sup>+</sup> T cells is associated with their activation and exhaustion, while CD57 serves as a senescence marker. The impact of PD-1<sup>+</sup> and CD57<sup>+</sup>CD8<sup>+</sup> T cells on the prognosis of patients with advanced high-grade serous ovarian cancer (HGSOC) remain unclear.</p><p><strong>Methods: </strong>We assessed the percentages of PD-1<sup>+</sup> and CD57<sup>+</sup>CD8<sup>+</sup> T cells in tumor-infiltrating lymphocytes (TILs, n=85) and tumor ascites lymphocytes (TALs, n=87) using flow cytometry. The optimal cutoffs for these markers in TILs and TALs were determined through the log-rank maximization method. Gene expression analysis elucidated the tumor immune microenvironment (TIME, n=36).</p><p><strong>Results: </strong>Patients with higher PD-1<sup>+</sup>CD8<sup>+</sup> TILs (>87.8%) exhibited longer platinum-free interval (PFI) and overall survival (OS). In contrast, those with elevated CD57<sup>+</sup>CD8<sup>+</sup> TALs (>28.69%) were more likely to experience chemotherapy and had lower complete remission rates, shorter PFI and OS. PD-1<sup>+</sup>CD8<sup>+</sup> TILs are primarily displayed an effector memory state with strong proliferative and secretory capabilities. Approximately 50% of CD57<sup>+</sup>CD8<sup>+</sup> TALs were terminally differentiated, exhibiting significantly impaired proliferation. Based on the proportions of PD-1<sup>+</sup>CD8<sup>+</sup> TILs and CD57<sup>+</sup>CD8<sup>+</sup> TALs, patients were categorized into good, median and poor prognosis groups, with median PFI of 47.78, 27.29 and 11.96 months, respectively (P<0.0001). Median OS for these groups was not reach, 49.23 and 30.92 months, respectively (P<0.0001). Patients with poor prognosis exhibit significantly reduced CD8<sup>+</sup> T cell proportion and increased M2 macrophage in the TIME, alongside downregulation of multiple T cell activation-related pathways.</p><p><strong>Conclusions: </strong>Lower levels of PD-1<sup>+</sup>CD8<sup>+</sup> TILs and higher CD57<sup>+</sup>CD8<sup>+</sup> TALs, assessed prior to treatment, correlated with poor prognosis and suppressive TIME in advanced HGSOC.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 1","pages":"73-89"},"PeriodicalIF":7.0000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893342/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2025.01.06","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The expression of programmed death 1 (PD-1) on CD8+ T cells is associated with their activation and exhaustion, while CD57 serves as a senescence marker. The impact of PD-1+ and CD57+CD8+ T cells on the prognosis of patients with advanced high-grade serous ovarian cancer (HGSOC) remain unclear.

Methods: We assessed the percentages of PD-1+ and CD57+CD8+ T cells in tumor-infiltrating lymphocytes (TILs, n=85) and tumor ascites lymphocytes (TALs, n=87) using flow cytometry. The optimal cutoffs for these markers in TILs and TALs were determined through the log-rank maximization method. Gene expression analysis elucidated the tumor immune microenvironment (TIME, n=36).

Results: Patients with higher PD-1+CD8+ TILs (>87.8%) exhibited longer platinum-free interval (PFI) and overall survival (OS). In contrast, those with elevated CD57+CD8+ TALs (>28.69%) were more likely to experience chemotherapy and had lower complete remission rates, shorter PFI and OS. PD-1+CD8+ TILs are primarily displayed an effector memory state with strong proliferative and secretory capabilities. Approximately 50% of CD57+CD8+ TALs were terminally differentiated, exhibiting significantly impaired proliferation. Based on the proportions of PD-1+CD8+ TILs and CD57+CD8+ TALs, patients were categorized into good, median and poor prognosis groups, with median PFI of 47.78, 27.29 and 11.96 months, respectively (P<0.0001). Median OS for these groups was not reach, 49.23 and 30.92 months, respectively (P<0.0001). Patients with poor prognosis exhibit significantly reduced CD8+ T cell proportion and increased M2 macrophage in the TIME, alongside downregulation of multiple T cell activation-related pathways.

Conclusions: Lower levels of PD-1+CD8+ TILs and higher CD57+CD8+ TALs, assessed prior to treatment, correlated with poor prognosis and suppressive TIME in advanced HGSOC.

PD-1 + CD8 +肿瘤浸润淋巴细胞和CD57 + CD8 +肿瘤腹水淋巴细胞的综合评分与晚期高级别浆液性卵巢癌患者的预后和肿瘤免疫微环境相关。
目的:程序性死亡1 (PD-1)在CD8+ T细胞上的表达与细胞的激活和衰竭有关,而CD57则是细胞衰老的标志。PD-1+和CD57+CD8+ T细胞对晚期高级别浆液性卵巢癌(HGSOC)患者预后的影响尚不清楚。方法:采用流式细胞术检测肿瘤浸润淋巴细胞(til, n=85)和肿瘤腹水淋巴细胞(tal, n=87)中PD-1+和CD57+CD8+ T细胞的百分比。通过对数秩最大化方法确定了这些标记在TILs和tal中的最佳截止点。基因表达分析阐明了肿瘤免疫微环境(TIME, n=36)。结果:PD-1+CD8+ TILs高的患者无铂间期(PFI)更长,总生存期(OS)更长。相比之下,CD57+CD8+ TALs升高的患者(>28.69%)更有可能经历化疗,完全缓解率更低,PFI和OS更短。PD-1+CD8+ til主要表现为效应记忆状态,具有较强的增殖和分泌能力。约50%的CD57+CD8+ tal呈终末分化,表现出明显的增殖受损。根据PD-1+CD8+ til和CD57+CD8+ tal的比例将患者分为预后良好组、中位组和预后差组,中位PFI分别为47.78、27.29和11.96个月(TIME中P+ T细胞比例升高,M2巨噬细胞增多,同时多种T细胞活化相关通路下调)。结论:治疗前评估的较低水平的PD-1+CD8+ til和较高水平的CD57+CD8+ tal与晚期HGSOC的不良预后和抑制时间相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
9.80%
发文量
1726
审稿时长
4.5 months
期刊介绍: Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信